Becton, Dickinson and Company (NYSE:BDX) will participate in the Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 8:30 AM ET. The company representatives include Tom Polen, the Chairman and CEO, and Chris DelOrefice, the Executive Vice President and CFO. We appreciate everyone joining us today for this call.
No matter if you invest in value, growth, or momentum, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.
FRANKLIN LAKES, N.J., Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a top global medical technology firm, has announced its participation in upcoming healthcare conferences. They will be presenting at Citi's 2025 Unplugged Medtech and Life Sciences Access Day on February 27, 2025, at 8:45 a.m.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons why you should make use of this tool.
The activist group Starboard has invested in Becton Dickinson and is urging the company to sell its life sciences division. Becton Dickinson is planning to follow this advice.
The financial results for Becton Dickinson (BDX) from the quarter ending in December 2024 provide insight into the company's performance. It may also be helpful to compare some important metrics with Wall Street predictions and figures from the same period last year.
On Wednesday, Becton Dickinson announced that its board has approved a plan to split off its life sciences division. This move is part of the company's strategy to concentrate on its main business.
BD (Becton, Dickinson and Company) reported strong financial results for the first quarter of fiscal 2025, with revenue reaching $5.2 billion, a 9.8% increase. The company's adjusted diluted earnings per share (EPS) rose to $3.43, marking a growth of 28%. Additionally, BD has completed a $750 million share repurchase and has raised its EPS guidance for the fiscal year.
According to a report from the Financial Times on Monday, activist investor Starboard Value has invested in Becton Dickinson and is urging the medical technology firm to sell its life sciences division.
The strong demand for BD's products is likely to have boosted revenues in the first quarter of the fiscal year, even with temporary changes in the market.